检索问题
依洛尤单抗的作用机制是什么？与他汀类药物相比，有什么优势？
依洛尤单抗（Evolocumab）是一种针对前蛋白转化酶枯草杆菌溶菌酶9型（PCSK9）的单克隆抗体，通过特异性结合并抑制PCSK9的功能，从而降低血浆低密度脂蛋白胆固醇（LDL-C）的水平。其作用机制主要体现在以下几个方面：
-
PCSK9抑制: 依洛尤单抗通过结合并中和PCSK9，防止PCSK9与肝细胞表面的LDL受体结合，进而提高这些受体的循环，增加LDL-C的清除率。这一过程导致肝脏对LDL-C的摄取能力显著增强，从而有效降低血浆中的LDL-C水平。
-
加速脂蛋白代谢: 研究表明，依洛尤单抗能够加速极低密度脂蛋白（VLDL）和中密度脂蛋白（IDL）等lipoprotein apoB的代谢速率，显著降低这些脂蛋白在血液中的浓度。依洛尤单抗可减少IDL-apoB和LDL-apoB的生成速率，这进一步帮助降低血液中LDL颗粒的数量。
与他汀类药物相比，依洛尤单抗具有以下优势：
-
更强的降胆固醇效果: 依洛尤单抗作为单药治疗时，可以将LDL-C水平降低50%-75%，比大多数他汀类药物的降胆固醇能力要显著。结合他汀类药物使用时，依洛尤单抗能够达到更大的LDL-C减少效果，这一组合治疗在临床试验中显示了更优的疗效。
-
对他汀不耐受患者的利好: 一部分患者对他汀类药物存在不耐受现象，出现肌肉疼痛、肝功能异常等不良反应。在这些患者中，使用依洛尤单抗作为替代治疗可以更好地管理胆固醇水平，而不会产生与他汀类药物相同的副作用。
-
降低心血管事件的潜在可能: 虽然关于依洛尤单抗能否显著降低心血管事件的假设尚待进一步验证，但由于其显著降低LDL-C水平的能力，理论上，它有潜力降低动脉粥样硬化性心血管疾病的发生率。
-
更少的药物相互作用: 他汀类药物在使用过程中可能会受到药物代谢酶的影响，导致药物浓度的变化，而依洛尤单抗的单克隆抗体性质使得药物的代谢相对稳定，影响药物效果的因素相对较小。
然而，依洛尤单抗的使用也不是全然没有争议，关于其长期安全性和经济效益的证据仍在积累中。在现代医学中，药物的选择应结合患者的具体情况，依洛尤单抗和他汀类药物有时也可能组合使用，以获得最佳的治疗效果。
总之，依洛尤单抗作为一种新型的PCSK9抑制剂，其作用机制与他汀类药物不同，并在某些方面展现了明显的优势，尤其是在高胆固醇和心血管疾病高风险患者的管理中，为患者提供了更多的治疗选择。
References
1Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.PubMed
Michael M Page, Gerald F Watts
Expert Opin Drug Metab Toxicol. 2015;11(9):1505-15. doi: 10.1517/17425255.2015.1073712.
INTRODUCTION: Statins are the mainstay of lipid-lowering therapies targeted at reducing cardiovascular risk. However, they do not completely obviate risk, not all patients tolerate them, and they are not sufficiently effective in patients with very high plasma levels of low-density lipoprotein-cholesterol (LDL-C) such as those with familial hypercholesterolemia (FH) or patients with elevated plasma levels of lipoprotein(a) [Lp(a)]. Recent advances in the understanding of lipoprotein metabolism have led to the development of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors including evolocumab , which lowers plasma levels of LDL-C by 50 - 75% as monotherapy or in combination with statin therapy. AREAS COVERED: We discuss in this review the rationale and background behind the development of evolocumab, and its pharmacodynamics and pharmacokinetics. We then discuss the current state-of-play of relevant clinical trials. EXPERT OPINION: The dramatic reduction in plasma levels of LDL-C attributable to evolocumab is anticipated to translate into lower rates of atherosclerotic cardiovascular disease, but this hypothesis remains to be proven. Also to be established are the long-term safety and economic benefits of evolocumab. PCSK9 inhibitors will also probably provide a valuable option for patients with statin intolerance, those with FH and patients with elevated plasma levels of Lp(a).
2Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.PubMed译依洛尤单抗和阿托伐他汀对脂蛋白代谢的量效作用。
et al.
Circulation. 2017 Jan 24;135(4):338-351. doi: 10.1161/CIRCULATIONAHA.116.025080. Epub 2016 Dec 9.
BACKGROUND: Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations. Evolocumab is under investigation for its effects on cardiovascular outcomes in statin-treated, high-risk patients. The mechanism of action of PCSK9 monoclonal antibodies on lipoprotein metabolism remains to be fully evaluated. Stable isotope tracer kinetics can effectively elucidate the mode of action of new lipid-regulating pharmacotherapies. METHODS: We conducted a 2-by-2 factorial trial of the effects of atorvastatin (80 mg daily) and subcutaneous evolocumab (420 mg every 2 weeks) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100 (apoB), intermediate-density lipoprotein-apoB, and LDL-apoB in 81 healthy, normolipidemic, nonobese men. The kinetics of apoB in these lipoproteins was studied using a stable isotope infusion of D3-leucine, gas chromatography/mass spectrometry, and multicompartmental modeling. RESULTS: Atorvastatin and evolocumab independently accelerated the fractional catabolism of VLDL-apoB (P<0.001 and P.032, respectively), intermediate-density lipoprotein-apoB (P=0.021 and P=.002, respectively), and LDL-apoB (P<0.001, both interventions). Evolocumab but not atorvastatin decreased the production rate of intermediate-density lipoprotein-apoB (P=0.043) and LDL-apoB (P<0.001), which contributed to the reduction in the plasma pool sizes of these lipoprotein particles. The reduction in LDL-apoB and LDL-cholesterol concentrations was significantly greater with combination versus either monotherapy (P<0.001). Whereas evolocumab but not atorvastatin lowered the concentration of free PCSK9, atorvastatin lowered the lathosterol/campesterol ratio (a measure of cholesterol synthesis/absorption) and apoC-III concentration. Both interventions decreased plasma apoE, but neither significantly altered lipoprotein lipase and cholesteryl ester protein mass or measures of insulin resistance. CONCLUSIONS: In healthy, normolipidemic subjects, evolocumab decreased the concentration of atherogenic lipoproteins, particularly LDL, by accelerating their catabolism. Reductions in intermediate-density lipoprotein and LDL production also contributed to the decrease in LDL particle concentration with evolocumab by a mechanism distinct from that of atorvastatin. These kinetic findings provide a metabolic basis for understanding the potential benefits of PCSK9 monoclonal antibodies incremental to statins in on-going clinical end point trials. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02189837.
3Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies.PubMed
Zaheer Qureshi, Mikail Khanzada, Adnan Safi, et al.
Ann Med Surg (Lond). 2024 Mar 12;86(5):2818-2827. doi: 10.1097/MS9.0000000000001945. eCollection 2024 May.
BACKGROUND: Cardiovascular diseases (CVD) persist as the leading cause of mortality globally, with atherosclerotic cardiovascular disease (ASCVD), including hypercholesterolaemia, being a significant contributor. Hyperlipidemia management includes various lipid-lowering drugs, including statins, Bempedoic acid, inclisiran, Lomitapide, ANGPTL3 inhibitors, and PCSK9 inhibitors. Statins have traditionally dominated lipid management therapies; however, a subset of patients remains unresponsive or intolerant to this therapy, necessitating novel therapeutic approaches. Tafolecimab, a promising and novel PCSK9 monoclonal antibody, demonstrated significant LDL-C reduction and a favourable safety profile in clinical trials. OBJECTIVE: This review aimed to discuss the role and efficacy of Tafolecimab in the management of hypercholesterolaemia. METHODS: The authors searched online databases, including PubMed, Scopus, and Embase, for articles related to talofecimab. DISCUSSION: The efficacy of Tafolecimab in diverse patient populations, including those with comorbid conditions and various lipid disorders, has been explored. Ongoing trials, such as CREDIT-1, CREDIT-2, and CREDIT-4, have provided valuable insights into Tafolecimab's potential as a lipid-lowering agent. Moreover, the drug's extended dosing interval may enhance patient compliance and reduce treatment costs. It has also been found that Tafolecimab has more affinity for PCSK9 and a longer duration of LDL-C reduction than other monoclonal antibody drugs such as evolocumab. Thus, this review focuses on Tafolecimab, a novel PCSK9 monoclonal antibody, its mechanism of action, clinical trial outcomes, safety profile, and potential role in hypercholesterolaemia management. Despite its assuring potential, the long-term impact of Tafolecimab on cardiovascular outcomes remains to be fully elucidated, necessitating further research. Regulatory authorities like the FDA and EMA should also evaluate Tafolecimab's risks and benefits. CONCLUSION: In conclusion, Tafolecimab shows potential as an innovative therapeutic option for hypercholesterolaemia, particularly in patients with specific risk factors, but warrants additional research.